Organogenesis Net Income Applicable To Common Shares from 2010 to 2026
| ORGO Stock | USD 3.76 0.08 2.08% |
Net Income Applicable To Common Shares | First Reported 2017-09-30 | Previous Quarter -3 M | Current Value 5.3 M | Quarterly Volatility 16.5 M |
Check Organogenesis Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Organogenesis Holdings' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 1.7 M or Selling General Administrative of 355.6 M, as well as many indicators such as Price To Sales Ratio of 0.95, Dividend Yield of 0.0034 or PTB Ratio of 1.19. Organogenesis financial statements analysis is a perfect complement when working with Organogenesis Holdings Valuation or Volatility modules.
Organogenesis | Net Income Applicable To Common Shares | Build AI portfolio with Organogenesis Stock |
Evaluating Organogenesis Holdings's Net Income Applicable To Common Shares across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Organogenesis Holdings's fundamental strength.
Latest Organogenesis Holdings' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Organogenesis Holdings over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Organogenesis Holdings' Net Income Applicable To Common Shares historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Organogenesis Holdings' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Organogenesis Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | 3,607,707 | |
| Geometric Mean | 2,722,174 | |
| Coefficient Of Variation | 897.34 | |
| Mean Deviation | 20,095,264 | |
| Median | (25,160) | |
| Standard Deviation | 32,373,292 | |
| Sample Variance | 1048T | |
| Range | 159.7M | |
| R-Value | 0.33 | |
| Mean Square Error | 998.7T | |
| R-Squared | 0.11 | |
| Significance | 0.20 | |
| Slope | 2,093,141 | |
| Total Sum of Squares | 16768.5T |
Organogenesis Net Income Applicable To Common Shares History
About Organogenesis Holdings Financial Statements
Organogenesis Holdings investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how Organogenesis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 17.9 M | 18.8 M |
Pair Trading with Organogenesis Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.Moving together with Organogenesis Stock
Moving against Organogenesis Stock
| 0.55 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.53 | DSGN | Design Therapeutics | PairCorr |
| 0.44 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.4 | ENGN | enGene Holdings Common | PairCorr |
| 0.39 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Organogenesis Holdings Correlation against competitors. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Biotechnology sector continue expanding? Could Organogenesis diversify its offerings? Factors like these will boost the valuation of Organogenesis Holdings. Anticipated expansion of Organogenesis directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organogenesis Holdings data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.222 | Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.31 | Return On Assets |
Investors evaluate Organogenesis Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organogenesis Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organogenesis Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between Organogenesis Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organogenesis Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organogenesis Holdings' market price signifies the transaction level at which participants voluntarily complete trades.